跳至主要内容
临床试验/NCT01039506
NCT01039506已完成不适用

A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer

Daiichi Sankyo Co., Ltd.1 个研究点 分布在 1 个国家目标入组 1,376 人开始时间: 2009年10月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,376
试验地点
1
主要终点
Progression free survival

研究概览

简要总结

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Metastatic colorectal cancer (adenocarcinoma)
  • UGT1A1 genotyped patients
  • Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents)

排除标准

  • Contraindication of CPT-11
  • Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) 3-4
  • Patients to receiving CPT-11 as adjuvant chemotherapy
  • History of pelvic irradiation

研究组 & 干预措施

UGT1A1 genotyped patients

UGT1A1 genotyped patients receive CPT-11 based regimens

干预措施: CPT-11 based regimens (Drug)

结局指标

主要结局

Progression free survival

时间窗: Within 3 years

Percentage of participants alive without disease progression

次要结局

  • Safety events(Within 3 years)
  • Overall survival(At 3 years)
  • Time to treatment failure(Within 3 years)
  • Response rate(from Day 1 (treatment) through disease progression (within 3 years))
  • Disease control rate(Within 3 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验